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Abstract
Background: The purpose, methods, data sources and assumptions behind the World Health Organization (WHO)
Cervical Cancer Prevention and Control Costing (C4P) tool that was developed to assist low- and middle-income
countries (LMICs) with planning and costing their nationwide human papillomavirus (HPV) vaccination program are
presented. Tanzania is presented as a case study where the WHO C4P tool was used to cost and plan the roll-out
of HPV vaccines nationwide as part of the national comprehensive cervical cancer prevention and control strategy.
Methods: The WHO C4P tool focuses on estimating the incremental costs to the health system of vaccinating
adolescent girls through school-, health facility- and/or outreach-based strategies. No costs to the user (school girls,
parents or caregivers) are included. Both financial (or costs to the Ministry of Health) and economic costs are
estimated. The cost components for service delivery include training, vaccination (health personnel time and
transport, stationery for tally sheets and vaccination cards, and so on), social mobilization/IEC (information,
education and communication), supervision, and monitoring and evaluation (M&E). The costs of all the resources
used for HPV vaccination are totaled and shown with and without the estimated cost of the vaccine. The total cost
is also divided by the number of doses administered and number of fully immunized girls (FIGs) to estimate the
cost per dose and cost per FIG.
Results: Over five years (2011 to 2015), the cost of establishing an HPV vaccine program that delivers three doses
of vaccine to girls at schools via phased national introduction (three regions in year 1, ten regions in year 2 and all
26 regions in years 3 to 5) in Tanzania is estimated to be US$9.2 million (excluding vaccine costs) and US$31.5
million (with vaccine) assuming a vaccine price of US$5 (GAVI 2011, formerly the Global Alliance for Vaccines and
Immunizations). This is equivalent to a financial cost of US$5.77 per FIG, excluding the vaccine cost. The most
important costs of service delivery are social mobilization/IEC and service delivery operational costs.
Conclusions: When countries expand their immunization schedules with new vaccines such as the HPV vaccine,
they face initial costs to fund critical pre-introduction activities, as well as incremental system costs to deliver the
vaccines on an ongoing basis. In anticipation, governments need to plan ahead for non-vaccine costs so they will
be financed adequately. Existing human resources need to be re-allocated or new staff need to be recruited for
the program to be implemented successfully in a sustainable and long-term manner.
Reaching a target group not routinely served by national immunization programs previously with three doses of
vaccine requires new delivery strategies, more transport of vaccines and health workers and more intensive IEC
activities leading to new delivery costs for the immunization program that are greater than the costs incurred
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when a new infant vaccine is added to the existing infant immunization schedule. The WHO C4P tool is intended
to help LMICs to plan ahead and estimate the programmatic and operational costs of HPV vaccination.
Keywords: Human papillomavirus (HPV), vaccines, immunization programs, costing, planning, United Republic of
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Background
Cervical cancer caused by infection with carcinogenic
types of human papillomavirus (HPV) is the second most
common cancer in women worldwide according to age-
standardized incidence rates (ASR). In 2008, there were
more than a half million new cases and 274,000 deaths
due to cervical cancer [1]. More than 85% of these cases
occurred in low- and middle-income countries (LMICs),
with the highest incidence rates in Sub-Saharan Africa,
South-Central Asia, Latin America and Melanesia [2]. The
United Republic of Tanzania has one of the highest cervi-
cal cancer burdens in the world and the highest in Eastern
Africa, with an ASR of 50.9 cases per 100,000 women.
The World Health Organization (WHO) recommends
routine vaccination of 9- to 13-year-old girls to protect
against HPV infections with types 16 and 18, which contri-
bute to the development of approximately 70% of cervical
cancers [3] in countries where: (1) the prevention of cervi-
cal cancer and/or other HPV-related diseases is a public
health priority; (2) vaccine introduction is programmati-
cally feasible; (3) sustainable financing can be secured; and
(4) the cost-effectiveness of vaccination strategies in the
country or region has been duly considered [3]. In most
LMICs, the vaccine price offered to the public sector (ran-
ging from US$15 to more than US$130 per dose) has been
a barrier for vaccine uptake. The GAVI Alliance (formerly
the Global Alliance for Vaccines and Immunization) is
opening a finance window to purchase HPV vaccine at or
about US$5 per dose in order to co-finance the vaccine
with GAVI-eligible countries that apply and receive
approval [4]. While the vaccine price is a key driver on the
cost side, national governments and donors will also need
to consider additional resources to support implementa-
tion costs associated with delivery of vaccine to a new tar-
get population that has not been routinely vaccinated
previously. To date, while vaccine delivery costs for small-
scale demonstration projects in India, Peru, Uganda, Viet-
nam [5] and Tanzania [6] have been reported, data are
lacking on large-scale, country-wide implementation costs.
Hence, information on the affordability of different HPV
vaccine delivery strategies in LMICs is limited.
As part of developing Tanzania’s national comprehen-
sive strategy for cervical cancer prevention and control,
the Ministry of Health and Social Welfare (MOHSW)
requested technical assistance from WHO to estimate the
service delivery costs of introducing HPV vaccine into the
country. This request was also in response to a MOHSW
agreement to accept a three-year donation of HPV vaccine
from the manufacturer. To address this request, WHO
and their consultants developed the Cervical Cancer Pre-
vention and Control Costing (C4P) tool in order to facili-
tate the decision-making process of program managers
and policy makers by generating information on the pro-
jected costs of introducing cervical cancer interventions.
The WHO C4P tool consists of a HPV Vaccine Module
and a Cervical Cancer Screening and Treatment Module.
As the latter component is still under development, this
paper will focus only on the HPV vaccination component
of the tool.
This paper aims to present the purpose, definitions,
methods, data sources and assumptions behind the generic
WHO C4P tool to assist LMICs with planning and costing
their nationwide HPV vaccination program. Furthermore,
Tanzania’s experience and cost results will be presented in
piloting the WHO C4P tool to scale up prevention inter-
ventions as part of their national comprehensive cervical
cancer prevention and control plan.
Methods
Purpose of the generic tool
The generic costing tool is a country-specific costing and
planning tool that facilitates data collection and enables
the user to estimate and project the value of incremental
(additional) resources required to add the country-wide
delivery of HPV vaccine to an existing immunization pro-
gram over a five-year period. In other words, it only esti-
mates the value of new resources needed and does not
include the cost of other goods and services (for example,
transport) already being used for other vaccines (shared
costs). For example, it does not estimate the cost of trans-
porting HPV vaccine if this is part of the same transport
used to deliver other vaccines such as rotavirus or tradi-
tional Expanded Program on Immunization (EPI) vaccines,
such as diphtheria, tetanus and pertussis (DTP) from the
central warehouse to the periphery in the country. Since
the WHO C4P tool focuses on estimating the incremental
costs of vaccinating adolescent girls from a public health
care provider perspective, no costs to the user (school
girls, parents and caregivers) are included.
Experience from the above-mentioned small-scale
demonstration projects showed [5,6] that the quantity of
resources required to introduce HPV vaccine for national
immunization programs (NIPs) will differ from those for
new infant vaccines since it has a non-traditional target
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population–annual cohorts of girls 9- to 13-years old.
Reaching this new and older target population with three
doses of vaccine requires new delivery infrastructure,
more transport for vaccines and health workers and
more intensive IEC activities, leading to higher costs per
vaccinated girl than costs per vaccinated infant for a new
infant vaccine. That is, since the vaccine may be adminis-
tered at venues such as schools or places in the commu-
nity additional costs are incurred for outreach.
The HPV Vaccine Module of the WHO C4P tool
enables the user to estimate the additional resource
requirements based on identifying different vaccine deliv-
ery scenarios that could potentially be considered for the
country. The tool allows the user to define different vac-
cine delivery strategies, for example, through schools,
health facilities or campaigns, such as national immuniza-
tion days. The tool provides estimates of several cost mea-
sures: (1) total costs of introducing the HPV vaccine in
specific regions/provinces or at the national level; (2) deliv-
ery cost per dose; and (3) delivery cost per fully immu-
nized girl (FIG) defined as the cost per dose multiplied by
the total number of doses delivered over three vaccination
rounds divided by the total number of girls who received
all three doses as a function of coverage and dropout rates
over all three vaccination rounds.
The generic version of the WHO C4P tool is built on
the experience of Tanzania. It was further developed and
critically assessed by costing experts representing five
WHO regions during a WHO workshop in December
2011 in Geneva. A beta version of the MS Excel tool (see
Figure 1 for a screenshot), including a User Guide, is
accessible through the WHO New and Under-Utilized
Vaccines Implementation (NUVI) website [7].
Cost categories and components of the tool
The WHO C4P tool allows the user to estimate the costs
of activities that take place during the introduction of
HPV vaccination into a national immunization program.
These activities include the following: procurement of vac-
cines and injection supplies, micro-planning, training,
social mobilization and IEC, purchase of cold chain equip-
ment, service delivery of vaccines to target population,
monitoring and evaluation, supervision and waste manage-
ment. Typical users of the WHO C4P tool are national
health planners without prior experience of HPV vaccine
introduction.
The tool differentiates recurrent (operational) and capi-
tal costs as well as financial and economic costs. It also
presents expenditures required for investments necessary
during the first years of HPV vaccine introduction.
Recurrent costs are defined as the value of resources
that last less than one year. These include program costs
such as the value of personnel time, transport, mainte-
nance, monitoring and evaluation, and supervision as well
as costs of short-term training activities that last less than
a year (for example, do not include material development
and initial training).
Capital costs are the value of resources that last longer
than one year, such as cold chain equipment and vehicles.
The capital goods and services used in HPV vaccination
include initial investments such as introduction costs
(micro-planning, initial training and social mobilization/
IEC material development) as well as additional cold chain
equipment, vehicle requirements and incinerators.
Both financial and economic costs are calculated in the
WHO C4P tool. The user can choose which one is most
appropriate depending on the objective of the analysis. If
the user wants to know the additional costs incurred or
actual expenditures by the Ministry of Health, for example,
they should focus on the financial cost calculation. Finan-
cial costs are the value of resources to the payer and
include the value of actual resources purchased for the
HPV vaccine introduction such as injection supplies, out-
reach allowances and per diem, resources used in training,
and developing new communication materials useful for
budgeting purposes.
Economic costs comprise the value of all outlays for vac-
cine introduction as well as those already paid for or
owned by the Ministry of Health and other sources of
financing, for example, the salaries of health personnel,
vaccines paid for by partners and time of volunteers. This
analysis is useful if the user is interested in evaluating the
share of different sources of finance for the vaccine intro-
duction. For example, they may want to know the share of
total costs financed by the Ministry of Health, external
partners, clients and the community. This analysis gives a
more complete picture of resources that are tied up in the
provision of the new vaccine and their opportunity costs
and should be used if a cost-effectiveness or cost-benefit
analysis is to be conducted.
Capital costs are calculated differently depending on
whether financial or economic costs are being estimated.
When calculating financial costs, straight-line depreciation
is used in the calculation of capital costs. In other words,
the cost of the item is annualized through dividing it by
the useful life years of the good. For example, cold chain
equipment could be expected to last for ten years and the
total cost would be divided by ten. Straight-line deprecia-
tion assumes that capital goods are used up equally over
the useful time period of the item. For economic costs,
capital goods are discounted (at a 3% default discount
rate) as well as annualized. This type of depreciation
assumes that people have time preference and prefer to
use goods and services now rather than in the future.
The main differences between financial and economic
costing are: (1) the time spent by health personnel, school
teachers and volunteers is valued in economic costing
since there is an opportunity cost to this time - for
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example, the workers are unable to spend time on other
activities when they are occupied with HPV vaccination -
but are not included in financial costs since these are
already paid for with government salaries; (2) the value of
donated goods and services is included in economic costs
but not in financial costs since there is an opportunity
cost to their use; and (3) capital costs are calculated differ-
ently for financial and economist costs.
For planning purposes the user is able to identify and
separate introduction costs (treated as a type of capital or
fixed costs) from recurrent costs. Introduction costs are
defined as resources required during the initial years of
vaccine introduction (some may occur during the second
or third year if the country has phased in vaccine intro-
duction) while the recurrent costs are the running costs of
the program such as transport of vaccines and health
workers, allowances and per diems and monitoring and
supervision.
Data sources and other assumptions of WHO C4P tool
During October 2010 to May 2011, data were collected
from the MOHSW/EPI on the costs of training, social
mobilization/IEC, vaccination, supervision, and monitor-
ing and evaluation. The study team collected primary and
secondary data on target populations, health facilities,
schools and costs of resources used to provide HPV vacci-
nation from the MOHSW website, and Ministry of Educa-
tion website (see also Table 1). The team also interviewed
MOHSW/EPI program managers and other partners
(WHO and UNICEF) to obtain information on program-
matic options and cost data. In addition, they supplemen-
ted these data with a survey on unit costs of hall rentals,
per diems, travel allowances and production costs for IEC
materials and training manuals. Furthermore, United
Nations Development Program (UNDP) population data
and the Tanzanian Comprehensive Multi-Year Plan
(cMYP) were used. Information was also collected from
the London School of Hygiene and Tropical Medicine
(LSHTM)/National Institute of Medical Research pilot
project of school-based introduction of HPV vaccination
in Mwanza province [6].
The data for the Tanzania analysis were taken from sev-
eral information sources, as can be seen in Table 1, ranging
from the MOHSW, the Ministry of Education (MOE) and
the Ministry of Finance (MoF). The population estimates
of ten-year-old girls were taken from UNDP.
The WHO C4P Vaccine Module: A case study for Tanzania
An overview of the basic assumptions of the HPV vacci-
nation program in Tanzania is summarized in Table 2.
It should be highlighted that, in this analysis, Tanzania
assumed that no additional costs for cold chain would
be required for HPV vaccine introduction.
Proposed HPV vaccine delivery strategy in Tanzania
The MOHSW of Tanzania is planning a phased school-
based delivery strategy, beginning in three regions of the
country, expanding to ten regions in the second year, and
covering 26 regions during the third through fifth years.
Nurses from health centers and dispensaries will travel to
schools to provide vaccinations to girls in the Primary 4
level in the schools. The health workers will visit each
school three to four times for planning and administration
of three vaccine doses to the girls.
In preparation for the vaccination, the MOHSW will
conduct trainings for health staff and develop and
Figure 1 Screenshot of C4P Tool.
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undertake sensitization meetings with communities, par-
ents and the media to inform the general population
about the benefits of the vaccination through IEC.
Planned activities in Tanzania
Training activities that are costed include a curriculum
development workshop and the following trainings: train-
ing of trainers (ToT) workshops, district supervisors and
vaccinators. Social mobilization and IEC activities
included the following: (1) a sensitization, mobilization
and communication guidelines and tools preparation
workshop; (2) a district campaign preparation workshop;
(3) materials development and production; (4) materials
printing and airing; (5) sensitization meetings with the
community; and (6) a media seminar for journalists.
Radio spots are projected to air all three years, but
national television advertisements will only take place in
the third year when the vaccination is introduced in all of
the regions, including Zanzibar.
The financial costs of service delivery are comprised of
per diems and transport allowances for the health worker
and per diems for the school teacher which have to be
paid on top of their regular salaries. Procurement costs
are incurred for receiving and storage of the vaccines at
the port and transport of the vaccines to the zonal level,
but do not include vaccine costs since these are donated
commodities. The monitoring and evaluation costs are
comprised of production costs for tally sheets and vacci-
nation cards. The costs of supervision are for transport
(fuel and maintenance of vehicles) and per diems
incurred during the quarterly visits from the national
level to the regions and districts. The waste management
costs are for construction of incinerators, fuel for incin-
erators and/or transport of waste.
Economic costs of service delivery include the value of
resources for financial costs as well as the value of the
time of personnel time and donated vaccines and capital
items.
Results
In the scenario examined, 1.6 million girls are fully vacci-
nated (that is, receive three doses) over five years out of a
total target population of 2.4 million girls (five cohorts of
ten-year-old girls in the five-year national program with
phased roll-out during years one to two and national vac-
cination starting in year three for an estimated three-dose
Table 1 Data Sources for Tanzanian Cost Analysis of HPV Vaccine Introduction.
Data Source
Number of 10 year old girls UNDP
Number of health facilities, types and number of health staff MOHSW
Number of primary schools Ministry of Education
Health Staff Salaries cMYP
Unit Costs of hall rentals, facilitator fees, and other meetingexpenses, production of IEC materialsa Survey of local costs
Unit costs of supplies MOHSW, WHO
Transport allowances and per diems MOHSW, WHO
Exchange and inflation rates Ministry of Finance
Vaccine cost Estimate from GAVI Alliance 2011
aThe unit cost of hall rentals, for example, includes the cost per day per hall rental for a meeting or training. This unit cost is multiplied by the number of days of
a meeting or training to get the cost of hall rental per training or meeting. cMYP, Comprehensive Multi-Year Plan (Tanzania); GAVI, Global Alliance for Vaccines
and Immunization; MOHSW, Ministry of Health and Social Welfare; UNDP, United Nations Development Plan; WHO, World Health Organization.
Table 2 Basic assumptions for HPV vaccination program in Tanzania.
Number Description of assumption
1. Vaccine will be phased in over three years: 3 regions the first year, 10 regions thesecond year, and all 26 regions the 3rd, 4th and 5th years.
2. Girls enrolled in Primary 4 are a proxy of 10-year-old girls.
3. Four visits will be made to each school for orientation and to reach all of the girls.
4. No additional costs for the cold chain will be required.
5. Transport for bringing the vaccine to the health facilities will be integrated into existingtransport for EPI vaccines.
6. The coverage for girls age 10 is 85%, 77% and 65% in the 1st, 2nd and 3rd roundrespectively, vaccine wastage is 5%, a buffer stock of 25%
is maintained.
7. The price per dose is assumed to be US$5 per dose based on the price offered to theGAVI Alliance by Merck.
8. The health worker spends half a day at each school and receives outreach per diem
9. The transport allowance from the health facility for a health worker to and from theschool costs on average 10,000 Tsh (US$6.30)
10. Vaccines will be donated during the first three years but MOHSW will pay for syringes,receiving, clearance, storage and transport of the
vaccines to the health facilities.
EPI, Expanded Program on Immunization; GAVI, Global Alliance for Vaccines and Immunization; MOHSW, Ministry of Health and Social Welfare.
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vaccine coverage of 65%.) Table 3 provides a summary of
the expected outputs of introducing HPV vaccines in
Tanzania.
The five-year cost of introducing a national phased-in
HPV vaccine program during 2011 to 2015 in Tanzania
is estimated to be US$9.2 million (excluding vaccine
costs) and US$31.5 million (with vaccine) assuming a
vaccine price of US$5 (GAVI 2011). This is equivalent
to a financial cost of US$5.77 per fully immunized girl,
excluding the vaccine cost.
Table 4 shows the breakdown of costs during the first
five years of the vaccine introduction by activities which
totals to US$31.5 million (with vaccines). Excluding pro-
curement, the largest share of costs goes towards social
mobilization and IEC, followed by service delivery.
Figure 2 shows a pie chart of the financial costs break-
down by activities of introducing HPV vaccine in Tanzania
during 2011 to 2015. These data show that substantial
funding is required for HPV vaccine delivery efforts
despite the fact the vaccine will be donated during the first
three years.
Figure 3 shows the economic costs of HPV vaccine by
cost component. The resource requirements over five
years that include shared costs (for example, transport or
salaries also used for other vaccines) are approximately US
$58 million.
Table 5 shows the financial and economic costs per dose
and FIG without and with vaccines during 2011 to 2015 in
terms of financial and economic costs. Without the vac-
cine costs the financial costs per dose and per FIG are US
$1.66 and US$5.77, respectively, while the economic costs
(including salary costs of MOHSW personnel) per dose
and per FIG are US$3.56 and US$12.40. The average cost
per dose and FIG are higher if the vaccine costs are
included, as shown in Table 5.
Table 6 shows an illustrative comparison using the
WHO C4P tool of school-based and health facility-based
scenarios in terms of financial introduction and recurrent
costs per eligible girl. The introduction costs during the
first three years of phased roll-out would be similar; how-
ever, the recurrent costs per dose and for three doses per
eligible girl would be higher for a school-based compared
to health facility-based delivery scenario because transpor-
tation costs of vaccines and personnel per diems will be
higher for the outreach.
Discussion
When countries expand their immunization schedule
with a new vaccine such as HPV, they face initial costs to
fund critical pre-introduction activities, as well as incre-
mental system costs to deliver the vaccines on an
ongoing basis. By using the WHO C4P, the Tanzania
experience of introducing HPV vaccine through a phased
school-based delivery strategy in all the 26 regions shows
that the five-year recurrent total costs of introducing
HPV vaccine (excluding vaccine cost) are around US$9.2
million, which is equivalent to US$5.77 per FIG to the
government. These recurrent costs correspond to 0.7% of
the government real expenditures on health, indicating
that substantial ministry of health government resources,
such as health personnel, are required to deliver the vac-
cine effectively. Actual resources required are dramati-
cally higher when one considers the vaccine costs and
shared costs included as part of the economic costs ana-
lysis, that is, approximately US$59 million over a five-
year period.
This study shows that, other than procurement, the
most important costs of service delivery are social mobili-
zation/IEC and service delivery operational costs. Social
mobilization and IEC activities are particularly important
to ensure that broad coverage is achieved by informing the
population about the benefits of HPV vaccination and
supporting the service delivery strategy used. Governments
need to plan ahead for these non-vaccine costs so that
they will be financed adequately and human resources
need to be re-allocated appropriately for the program to
be successfully implemented in a sustainable and long-
term manner.
To date, data availability on national HPV vaccination
in LMICs is limited, which makes it difficult to validate
the tool. However, the findings from the WHO C4P tool
for Tanzania are consistent with existing information on
recurrent costs from various small-scale demonstration
projects from the Program for Appropriate Technology
Table 3 Summary of expected outputs of introducing HPV vaccines in Tanzania, 2011-2015.
Output 2011 2012 2013 2014 2015 Total
Target population 80,290 349,349 646,936 672,833 694,666 2,444,074
Doses useda 181,878 791,362 1,471,308 1,524,135 1,573,591 5,542,274
Fully immunized girls 52,209 227,164 422,345 437,510 451,706 1,590,934
Health workers trained 1,472 3,596 5,070 0 0 10,138
Health facilities mobilized 736 1,798 2,535 0 0 5,069
School vaccination sites added 2,098 6,333 7,727 0 0 16,158
Schools sensitized 2,098 6,333 7,727 0 0 16,158
aDoses used include doses administered, wastage and buffer. HPV, human papillomavirus.
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in Health (PATH) in India, Peru, Uganda and Vietnam
[5] and the LSHTM project in Mwanza province in Tan-
zania [6]. Furthermore, the WHO C4P tool for Tanzania
findings are also consistent with scale-up cost estimates
for national HPV vaccination studies using the WHO
C4P tool for Uganda [6], Bhutan and Rwanda based on
actual HPV vaccine introduction with actual expenditure
data (personal communication with responsible EPI offi-
cers from Bhutan and Rwanda)a. These studies demon-
strate that introduction costs for HPV vaccines are
higher than those for existing vaccines such as meningitis
A campaigns and combination DTP-HepB-Hib vaccine
via routine infant EPI vaccination programs [8,9] due to
increased needs for IEC and social mobilization activities
to sensitize the public about the benefits of HPV vaccines
for adolescent girls.
From the nationwide-modeled experiences based on
PATH demonstration projects, the average introduction
costs per eligible girl are US$2.99 (range US$2.82 to US
$3.07) and the recurrent costs to deliver three doses per
eligible girl are US$4.17 (range US$3.51 to US$4.78) [5].
As HPV vaccine introduction requires building up a
new delivery infrastructure, the costs are significantly
higher. From the three available projected nationwide-
modeled HPV vaccination costing studies in Tanzania,
Uganda and Bhutan, the average cost is about US$3.00
per 10-year old girl.
The resource requirements of IEC activities are a large
component of total costs since these are considered to be
important aspects for a successful introduction of HPV
vaccination, a new vaccine that targets a non-traditional
population of adolescent girls. The population will need to
be assured of its safety and benefits and be provided with
an explanation of why this vaccination is given only to
girls and not boys. The costs of IEC activities are calcu-
lated for the following activities: (1) sensitization meetings
with community leaders to inform them of the benefits of
the intended vaccination activities; (2) production of














Procurementa 132,880 552,459 963,346 10,162,160 10,491,906 22,302,751
Training b 140,489 203,783 298,912 - - 643,184
Social mobilization and IEC 191,431 472,009 941,007 661,853 668,039 2,934,340
Service Deliveryc 97,907 393,447 754,040 754,040 754,040 2,753,473
M and E, Supervisiond 50,181 97,191 171,731 171,731 171,731 662,564
Othere 72,972 312,303 583,713 602,214 619,534 2,190,735
Totals 685,860 2,031,190 3,712,749 12,351,998 12,705,250 31,487,047
aProcurement includes the cost of vaccines, including shipping, receiving and storage, plus 5% wastage, and buffer stock; btraining includes costs of transport to
the meeting venues, supplies, facilitators, hall rentals, and personnel allowances and lodging; cservice delivery includes transport to schools, outreach per diems/
allowances for health workers and school teachers, and health workers and school teacher time (for economic costs); dmonitoring and evaluation and supervision
include monitoring forms, vaccination cards, transport for supervisory visits, and health worker personnel allowances and lodging; eother includes fuel and
transport for waste management. IEC, information, education and communication; M and E, management and evaluation.
Figure 2 Financial costs of HPV vaccine delivery, 2011 to 2015.
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leaflets and posters on the benefits of HPV vaccinations to
be placed by service providers in clinics, schools and pub-
lic locations in their catchment areas; (3) design and pro-
duction of radio and/or television announcements on the
HPV vaccine for the population; and (4) briefings with
writers, journalists, editors, publishers and other media
personnel to inform them about the benefits of the vac-
cine. As HPV vaccination is scaled up in these countries,
more IEC activities will be required, given that airing of
radio and TV announcements will be more effective once
the vaccination is scaled up nationally.
The WHO C4P tool in its current version has several
limitations. First, depending on the countries’ characteris-
tics, additional sizable costs might be expected from a soci-
etal perspective that are not included in the WHO C4P
tool, such as private costs to schoolgirls, parents and care-
givers and additional costs for the cold chain. Variation in
the incremental cost to the health system of vaccinating
adolescent girls by different countries is expected and can
potentially be explained by country characteristics, such as
size of the country, population density and proximity of
health facilities to schools, current infrastructure of schools
and health facilities and national income level as well as
the intensity of the HPV vaccine introduction effort (Levin
et al. in preparation). Secondly, monitoring and evaluation
costs are restricted to production of tally sheets and vacci-
nation cards. In reality, additional quality control or evalua-
tive measures, such as cost of administrative personnel to
evaluate coverage levels might be required.
Past experience from the African region for delivery of
other adolescent health interventions such as school
deworming programs with benzimidazoles [10] and
school-targeted treatment for Schistosoma mansoni [11]
suggest lower cost estimates per child compared to deli-
vering an adolescent vaccine. More recently, costing data
is becoming available on the delivery and scaling up of
sexual and reproductive health interventions through ado-
lescent-friendly health services. Pilot testing of a WHO
costing tool in Uganda in 2006 found unit costs per ado-
lescent child ranging from US$4.50 for sexually trans-
mitted infection (STI) treatment in a public primary
health facility to US$19 for HIV counseling and testing in
a non-governmental organization (NGO)-run facility [12].
Overall, however, accurate cost estimates of interventions
delivered to young people are rare and more needs to be
done to improve evaluations of the economic value of
investments targeted at this age group [13].
In anticipation of these additional service delivery costs
for HPV vaccines as an example for non-traditional vac-
cines, the GAVI Alliance is reviewing its current policy
towards vaccine introduction grants and operational sup-
port for campaigns [14]. GAVI’s introduction grant is a
one-time cash grant to fund some of the activities asso-
ciated with adopting a new vaccine in a country’s national
Figure 3 Economic costs of HPV Vaccine, 2011 to 2015.
Table 5 Financial and economic cost per dose and per
fully immunized girl without and with vaccine costs
(2011 US$).











1.66 3.56 5.68 10.62
Cost per
FIGa
5.77 12.40 19.79 37.01
aThe coverage of FIG is 65% assuming coverage rates for girls age 10 of 85%,
77% and 65% in the 1st, 2nd and 3rd round, respectively. FIG, fully immunized
girl.
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immunization program [15]. However, the vaccine intro-
duction grant does not fund the total costs resulting from
a new vaccine introduction. Governments and partners
are expected to contribute additional funding in order to
facilitate an effective introduction. Past experience has
shown that governments have not always been able to
quickly mobilize additional funding from their own bud-
gets or development partners to fill these funding gaps.
The WHO C4P tool could be used to assist countries in
estimating the pre-introduction and incremental system
costs to deliver the HPV vaccine.
Use of an early version of the Cervical Cancer
Screening and Treatment Module of the WHO C4P
tool demonstrates that the preliminary costs of scaling-
up screening and treatment in Tanzania are estimated
to be $12.1 million over five years. In the scenario
examined, 1.2 million out of a target population of five
million women are screened using visual inspection
with acetic acid (VIA), while 17.4 thousand women out
of 60 thousand VIA-positive women receive treatment.
This estimate is based on screening at the health dis-
pensary level and above and treatment at the health
center level and above [16]. Completion of the Cervical
Cancer Screening and Treatment Module of the WHO
C4P tool will further contribute to the decision-making
process.
Finally, HPV vaccines are not the only new vaccines
being considered for introduction in LMICs. There are
also pneumococcal and rotavirus vaccines as well as sev-
eral older vaccines that have not yet been broadly adopted
in developing countries. Although intended for national
HPV vaccination costing and planning purposes, the eco-
nomic cost results of the WHO C4P tool can be used as
an input for cost-effectiveness analysis and/or budget
impact analysis in order to assist countries in setting their
priorities between competing vaccines or other cervical
cancer control options. In-country cost estimates of the
programmatic costs of delivering an adolescent vaccine
and scaling up of cervical cancer screening and treatment
interventions as an input for cost-effectiveness analysis are
rare. For instance, a health and economic impact study of
HPV vaccination and cervical cancer screening in five
Eastern African countries would have benefited from a
country-specific data collection and projection costing tool
such as WHO C4P to estimate these programmatic costs
[17] among other tools.
Conclusions
The financial delivery costs of nationwide HPV vaccina-
tion are higher than those of infant vaccines and can be
substantial in resource-poor settings since it requires
building up new delivery channels. As a consequence,
governments need to plan ahead for these non-vaccine
costs so that they will have adequate finances in place
for vaccine introduction.
As GAVI’s vaccine portfolio is expanding and coun-
tries are expected to introduce new vaccines at an
increasing rate, it is recommended to include (partial)
funding for operational health system costs in order
assist GAVI eligible countries in introducing HPV vac-
cines. Together with other decision-making tools, the
WHO C4P tool could facilitate both low- and middle-
income countries in demonstrating their ability to deli-
ver HPV vaccines nationwide to the target population in
an effective, sustainable and affordable manner.
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Introduction costs per eligible girl 3.07 3.07
Recurrent cost per dose 1.59 1.17
Recurrent costs for three doses per eligible girl 4.78 3.51
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